Long
Long TP at $2.50
ZGNX Brean initiation report (partial) Future Looks Brighter for Zogenix, Initiate with BUY and $2.50 TP Investment Summary
We are initiating coverage of Z, Inc. with a BUY rating and a $2.50 TP. Zogenix has commercialized
a controversial product, Z ER, and we believe the market under-appreciates the medical value this
product brings to patients and pain-treating specialists. Despite the heated debate and intense negative
coverage from the media, we are impressed that the product is performing well during early launch days.
We are initiating coverage of Z, Inc. with a BUY rating and a $2.50 TP. Zogenix has commercialized
a controversial product, Z ER, and we believe the market under-appreciates the medical value this
product brings to patients and pain-treating specialists. Despite the heated debate and intense negative
coverage from the media, we are impressed that the product is performing well during early launch days.
Declinazione di responsabilità
Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.